Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib with Camrelizumab and TPC in TNBC
NCT05760378Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of famitinib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Mar 2023; status: recruiting.
02
Drugs
famitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05760378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760378.